Skip to main content
    I

    Intellia Therapeutics Inc (NTLA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $9.78
    -0.08 (-0.81%)

    Market Cap: $1.36B

    Last updated: Nov 17, 2026 at 4:41 PM ET

    Intellia Therapeutics Inc (NTLA) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Intellia Therapeutics (NTLA) has a market cap of $1.36B and an enterprise value of $1.28B. It kept -805.75% of revenue as net income over the last 12 months. Its share count is up 27.22% from a year earlier.

    Total Valuation

    Enterprise value is 6.05% below the market cap, as cash exceeds debt.

    Market Cap$1.36B
    Enterprise Value$1.28B
    Latest price (Nov 17, 2026)$9.78

    Key Dates

    The next earnings report is expected on Feb 24, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateFeb 24, 2027 (expected)
    Last Earnings DateNov 5, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 5.02% in the quarter ended Sep 30, 2026 and grew 17.81% a year over 2 years.

    Shares Outstanding140.19M
    Shares Change (YoY)+27.22%
    Shares Change (QoQ)+5.02%
    Share Count Growth (2Y CAGR)+17.81%

    Valuation Ratios

    Sales and book value multiples are 25.9x and 2.2x. Its year-end P/S ranged from 4.2x to 255.7x from 2016 to 2025.

    P/S Ratio25.9x
    Forward P/S31.4x
    P/B Ratio2.2x

    Valuation history and multiples

    Price Statistics

    The stock is up 12.41% over 52 weeks and trades 17.12% below its 50-day average.

    Beta (1Y)2.32
    52-Week Change+12.41%
    1-Month Change-15.54%
    3-Month Change-26.36%
    6-Month Change-18.09%
    5-Year Change-90.62%
    10-Year Change-9.51%
    Total Return (1Y)+12.41%
    Total Return (3Y CAGR)-29.67%
    Total Return (5Y CAGR)-40.86%
    Return vs SPY (1Y)+3.91%
    Max Drawdown (1Y)-45.63%
    Max Drawdown (3Y)-80.85%
    Sharpe Ratio (1Y)0.19
    Correlation with SPY (1Y)0.43
    50-Day Average$11.80
    200-Day Average$12.92
    52-Week Range$7.95 to $18.48
    RSI (14 Days)37.3
    Average Volume (20 Days)4.63M

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 6.31x current liabilities, and total debt is 0.12x shareholder equity.

    Current Ratio6.31x
    Quick Ratio6.31x
    Debt / Equity0.12x

    Returns and Efficiency

    Return on invested capital is -50.04% over the last 12 months, against a 5-year average of -51.84%.

    Return on Equity (ROE)-69.51%
    Return on Assets (ROA)-47.21%
    Return on Invested Capital (ROIC)-50.04%
    ROE (5Y Average)-46.19%
    ROA (5Y Average)-36.29%
    ROIC (5Y Average)-51.84%
    Asset Turnover0.06x
    Receivables Turnover7.14x

    Scores

    NTLA has an Altman Z-Score of -2.65, in the distress zone below 1.81, and a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.

    Altman Z-Score-2.65
    Altman Z ZoneDistress
    Piotroski F-Score2 of 9
    Piotroski StrengthWeak

    Income Statement

    Revenue of $52.89M over the last 12 months is down 8.07% from the 12 months before.

    Revenue$52.89M
    Revenue Growth (YoY)-8.07%
    Gross Profit$52.89M
    Operating Income-$434.33M
    Pretax Income-$426.88M
    Net Income-$426.14M
    EBITDA-$425.35M
    Reported EPS (TTM)-$3.35

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 67.93% of the $902.56M in total assets.

    Cash and Equivalents$156.10M
    Total Debt$73.73M
    Net Cash$82.37M
    Net Cash Per Share$0.59
    Working Capital$426.04M
    Shareholder Equity$613.09M
    Book Value Per Share$4.37
    Total Assets$902.56M
    Total Liabilities$289.47M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    After $2.90M of capital spending, operating cash flow left -$358.08M of free cash flow.

    Operating Cash Flow-$355.17M
    Capital Expenditures$2.90M
    Free Cash Flow-$358.08M
    FCF Per Share-$2.56
    Depreciation and Amortization$13.06M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -821.24%.

    Gross Margin100.00%
    Operating Margin-821.24%
    Pretax Margin-807.16%
    Net Margin-805.75%
    EBITDA Margin-804.26%
    FCF Margin-677.06%

    Growth

    Revenue grew 9.09% a year over 3 years.

    Revenue Growth (3Y CAGR)+9.09%
    Revenue Growth (5Y CAGR)+3.13%
    Book Value Per Share Growth (2Y CAGR)-26.95%
    Tangible Book Per Share Growth (2Y CAGR)-26.95%

    Revenue and profit by year

    Dividends and Yields

    NTLA does not pay a dividend. Its free cash flow yield is -26.12%.

    FCF Yield-26.12%
    Buyback Yield-16.85%
    Shareholder Yield-16.85%

    Peer Position

    Against 8 similar companies, NTLA has the 4th highest P/S.

    P/S Ratio25.9x vs 16.4x median
    ROIC-50.04% vs -29.73% median
    Revenue Growth (Trailing 4 Quarters, YoY)-8.07% vs +18.14% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at 32.61% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)+32.61%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    GNG Valuation

    GNG viewUndervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About NTLA

    What is NTLA's market cap?

    Intellia Therapeutics has a market cap of $1.36B. Its enterprise value, which adds debt and subtracts cash, is $1.28B.

    How many shares of NTLA are outstanding?

    Intellia Therapeutics has 140.19M shares outstanding. The count is up 27.22% from a year earlier.

    Does NTLA pay a dividend?

    No. Intellia Therapeutics does not pay a dividend.

    How much debt does NTLA have?

    Intellia Therapeutics has $73.73M of total debt and $156.10M of cash and equivalents, a net cash position of $82.37M.